Yang and colleagues have previously reported a clinically guided culture method to generate allogeneic CAR-NKT cells by engineering human hematopoietic stem and progenitor cells. As potential application, here the authors describe the design and characterization of allogeneic CD33-targeting CAR-NKT cells, showing anti-tumor activity in preclinical models of bone marrow-resident myeloid malignancies.
- Yan-Ruide Li
- Ying Fang
- Lili Yang
